Skip to content
OpenCapital
Get started

Haemonetics HAE Asia — Net revenues

Other geography segments

Europe
$52.9M+25.1%
Rest of Asia
$19.97M-5.6%
Other
$3.11M+12.3%
Other Countryor Region
$1.81M-63.3%

Similar metrics at other companies

TFX
TFXAsia — Net revenues
$68.93M+64.5%
Morgan Stanley logo
MSAsia — Net revenues
$3.35B+42.8%
ROP
ROPAsia — Net revenues
$17.78M-4.0%
Materion logo
MTRNAsia — Net Sales
$144.13M+13.4%
Ralph Lauren logo
RLAsia — Net revenues
$563.7M+30.6%
Levi Strauss & Co. logo
LEVIAsia — Net revenues
$347.5M+12.8%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.37B-18.0%
Enterprise value$4.4B-12.5%
P/S2.5×-0.5×

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's asia — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's asia — net revenues?
Haemonetics (HAE) reported asia — net revenues of $23.03M in Q4 2025.
How has Haemonetics's asia — net revenues changed year-over-year?
Haemonetics's asia — net revenues decreased by 10.0% year-over-year, from $25.6M to $23.03M.
What does asia — net revenues mean?
This metric represents the total net revenue generated from sales of medical products and solutions within the Asian geographic market. It reflects the company's regional market penetration and the adoption rate of its blood and plasma component collection technologies in these specific territories. Monitoring this figure helps investors assess the company's international growth strategy and its ability to capture market share in emerging or established healthcare systems outside of its primary domestic markets.